Cat. No. | Product name | CAS No. |
DC8414 |
MI-77301 (SAR405838)
Featured
MI-77301 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1. |
1303607-60-4 |
DC10074 |
MX69
Featured
MX69 is the MDM2/XIAP inhibitor, used for cancer treatment. |
1005264-47-0 |
DC7879 |
NSC 66811
NSC 66811 is a potent MDM2 inhibitor (Ki = 120 nM). |
6964-62-1 |
DC8746 |
NSC319726
NSC319726 is a mutant p53R175 reactivator; inhibits growth of fibroblasts expressing the p53R175 mutation (IC50 = 8 nM); shows no inhibition for p53 wild-type cells. |
71555-25-4 |
DC9257 |
NSC59984
Featured
NSC59984 induces mutant p53 protein degradation via MDM2 and the ubiquitin-proteasome pathway.The EC50 of NSC59984 in most cancer cells is significantly lower than those of normal cells, with EC50 of 8.38 μM for p53-null HCT116 cells. |
803647-40-7 |
DC3125 |
Nutlin-3
Featured
Nutlin 3 is a commercial available p53-MDM2 inhibitor, with Ki of 90 nM. |
548472-68-0 |
DC8454 |
Nutlin-3a
Featured
Nutlin-3a is arbitrarily referred to as enantiomer a because it appears as the first peak from chiral purification of racemic nutlin-3 and its absolute stereocenter assignment is not known. |
675576-98-4 |
DC8455 |
Nutlin-3b
Nutlin-3b is 150-fold less potent as an inhibitor of p53-MDM2 interaction than (−)-nutlin-3, demonstrating an IC50 value of 13.6 µM. |
675576-97-3 |
DC8144 |
Pifithrin-β (hydrobromide)
Featured
Pifithrin-β HBr (Cyclic Pifithrin-α HBr) is a potent p53 inhibitor with IC50 of 23 uM in an antiproliferative assay in the human ovarian carcinoma cell line, IGROV-1. |
511296-88-1 |
DC9902 |
PRIMA-1
Featured
PRIMA-1 is a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A. |
5608-24-2 |
DC10070 |
PRIMA-1MET(APR-246)
Featured
PRIMA-1MET is methylated derivative of PRIMA-1. It can restore mutant p53 activity. |
5291-32-7 |
DC8865 |
RG-7112
Featured
RG7112 (RO5045337) is an orally bioavailable and selective p53-MDM2 inhibitor. |
939981-39-2 |
DC8467 |
RO8994
Featured
RO8994 is a potent and selective spiroindolinone MDM2 inhibitor for cancer therapy. |
1309684-94-3 |
DC9506 |
SJ-172550
Featured
SJ-172550 is the first MDMX inhibitor with EC50 of 0.84 uM; binds reversibly to MDMX and effectively kills retinoblastoma cells in which the expression of MDMX is amplified. |
431979-47-4 |
DC8599 |
SP 141
Featured
SP 141 is a cell-permeable inhibitor of Mdm2 (Ki = 28 nM). |
1253491-42-7 |
DC7314 |
Tenovin-3
Featured
Tenovin-3 is a small molecule activator of p53 transcriptional activity. |
1011301-27-1 |
DC9504 |
YH239-EE
Featured
YH239-EE, ethyl ester of the free carboxylic acid compound YH239, is a potent p53-MDM2 antagonizing and apoptosis-inducing agent |
1364488-67-4 |
DC10851 |
PK11000
Featured
PK11000 is an alkylating agent, and stabilizes the DNA-binding domain of both WT and mutant p53 by covalent cysteine modification, without compromising DNA binding. |
38275-34-2 |
DC28442 |
Pifithrin-α, p-Nitro, Cyclic
Pifithrin-α, p-Nitro, Cyclic (PFN-α) is cell-permeable and active-form p53 inhibitor. Pifithrin-α, p-Nitro, Cyclic is one order magnitude more active than Pifithrin-α in protecting cortical neurons exposed to Etoposide (ED50=30 nM). Pifithrin-α, p-Nitro, Cyclic behaves as a p53 posttranscriptional activity inhibitor. Pifithrin-α, p-Nitro, Cyclic do not prevent p53 phosphorylation on the S15 residue. |
60477-38-5 |
DC28687 |
MDM2-IN-1
MDM2-IN-1 (Compound 30) is a synthetic MDM2-p53 interaction (MDM2) inhibitor and contains the trans (D-)configuration. |
1410737-09-5 |
DC40025 |
Milademetan tosylate hydrate
Milademetan (DS-3032) tosylate hydrate is a specific and orally active MDM2 inhibitor for the research of acute myeloid leukemia (AML) or solid tumors. Milademetan (DS-3032) tosylate hydrate induces G1 cell cycle arrest, senescence and apoptosis. |
2095625-97-9 |
DC42132 |
Triglycidyl isocyanurate
Triglycidyl isocyanurate (TGIC; Teroxirone) is a triazene triepoxide with antiangiogenic and antineoplastic activities. Triglycidyl isocyanurate inhibits the growth of non-small-cell-lung cancer cells via?p53 activation. Triglycidyl isocyanurate induces cell apoptosis. Triglycidyl isocyanurate can be used for cancer research. |
2451-62-9 |